FDA Approves First Ocular Drug Delivered by Suprachoroidal Injection
October 25, 2021U.S. FDA Approves Vuity Eye Drops for Presbyopia
October 29, 2021October 27, 2021 – The U.S. FDA has expanded the indication for cutaquig® [immune globulin subcutaneous (human)-hipp] 16.5% solution to include pediatric patients who are at least two years old. The drug was previously approved only for use in adults.
- First FDA approved in 2018, cutaquig is indicated to treat primary humoral immunodeficiency, a group of more than 80 chronic conditions that compromise the immune system.
- Recommended dosing is determined by a variety of factors, including the patient's age, treatment history, and clinical response to therapy.
- A subcutaneous injection manufactured by Octapharma, cutaquig can be administered by a healthcare provider or by a caregiver or the patient.